Tag: altepase

1. Patients presenting between 4.5 and 9 hours after stroke onset with viable brain tissue who received thrombolytic therapy had better neurological outcomes compared to those receiving placebo. 2. Symptomatic intracranial hemorrhage occurred in a higher number of patients in the thrombolysis group compared to placebo group. Evidence Rating Level: 1...
1. Patients presenting between 4.5 and 9 hours after stroke onset with viable brain tissue who received thrombolytic therapy had better neurological outcomes compared to those receiving placebo. 2. Symptomatic intracranial hemorrhage occurred in a higher number of patients in the thrombolysis group compared to placebo group. Evidence Rating Level: 1...
Intravenous thrombolytic therapy with alteplase (recombinant human tissue plasminogen activator) is approved for the treatment of acute ischemic stroke. However, whether it is efficacious in the treatment of lacunar infarcts remains unclear. In this secondary post-hoc analysis of the WAKE-UP randomized controlled trial, 108 patients with acute lacunar stroke...